Implementation of Continuous Glucose Monitoring in the Hospital: Emergent Considerations for Remote Glucose Monitoring During the COVID-19 Pandemic.

Abstract

Continuous glucose monitoring (CGM) has become a widely used tool in the ambulatory setting for monitoring glucose levels, as well as detecting uncontrolled hyperglycemia, hypoglycemia, and glycemic variability. The accuracy of some CGM systems has recently improved to the point of manufacture with factory calibration and Food and Drug Administration clearance for nonadjunctive use to dose insulin. In this commentary, we analyze the answers to six questions about what is needed to bring CGM into the hospital as a reliable, safe, and effective tool. The evidence to date indicates that CGM offers promise as an effective tool for monitoring hospitalized patients. During the current coronavirus disease 2019 crisis, we hope to provide guidance to healthcare professionals, who are seeking to reduce exposure to SARS-Cov-2, as well as preserve invaluable personal protective equipment. In this commentary, we address who, what, where, when, why, and how CGM can be adopted for inpatient use.

• Authors: Rodolfo J Galindo, Grazia Aleppo, David C Klonoff, Elias K Spanakis, Shivani Agarwal, Priya Vellanki, Darin E Olson, Guillermo E Umpierrez, Georgia M Davis, Francisco J Pasquel
• Journal: Journal of diabetes science and technology (J Diabetes Sci Technol) Vol. 14 Issue 4 Pg. 822-832 (Jul 2020) ISSN: 1932-2968 [Electronic] United States
• PMID: 32536205 (Publication Type: Journal Article)

Chemical References

• Blood Glucose

Topics

• Betacoronavirus
• Blood Glucose (analysis)
• Blood Glucose Self-Monitoring (methods)
• COVID-19
• Calibration
• Communicable Disease Control
• Coronavirus Infections (epidemiology)
• Diabetes Complications (therapy)
• Diabetes Mellitus (blood, therapy)
• Electronic Health Records
• Hospitalization
• Hospitals
• Humans
• Hyperglycemia (blood, complications, diagnosis)
• Inpatients
• Insulin Infusion Systems
• Monitoring, Ambulatory
• Pandemics
• Pneumonia, Viral (epidemiology)
• SARS-CoV-2
• United States
• United States Food and Drug Administration